Rhenman & Partners Asset Management AB
Reported holdings as of Q2 2026, from 31 quarterly filings.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| UNITEDHEALTH GROUP INC | UNH | $38.9M | 93,600 | +2.15pp | 31q | +105.7%+$20.0M | |
| CVS HEALTH CORP | CVS | $28.9M | 279,374 | -0.25pp | 8q | -17.0%-$5.9M | |
| ASTRAZENECA PLC | AZN | $28.5M | 151,500 | - | new | NEW | |
| MERCK & CO INC | MRK | $27.4M | 213,500 | - | new | NEW | |
| ELI LILLY & CO | LLY | $26.8M | 22,315 | -1.30pp | 13q | -33.8%-$13.7M | |
| ABBVIE INC | ABBV | $24.4M | 96,775 | +0.38pp | 28q | +35.2%+$6.3M | |
| ALIGNMENT HEALTHCARE INC | ALHC | $23.7M | 997,083 | -0.05pp | 16q | -5.4%-$1.3M | |
| EDWARDS LIFESCIENCES CORP | EW | $23.5M | 260,000 | +0.61pp | 5q | +59.5%+$8.8M | |
| GILEAD SCIENCES INC | GILD | $22.5M | 178,250 | -0.76pp | 25q | +6.3%+$1.3M | |
| JAZZ PHARMACEUTICALS PLC | JAZZ | $21.1M | 87,440 | +0.22pp | 31q | +15.2%+$2.8M | |
| BIOGEN INC | BIIB | $20.5M | 94,850 | -0.53pp | 16q | -13.1%-$3.1M | |
| STRYKER CORPORATION | SYK | $20.5M | 65,000 | -0.01pp | 2q | +36.0%+$5.4M | |
| BOSTON SCIENTIFIC CORP | BSX | $19.2M | 450,500 | -3.02pp | 31q | -27.9%-$7.4M | |
| JOHNSON & JOHNSON | JNJ | $18.4M | 72,500 | - | new | NEW | |
| GUARDANT HEALTH INC | GH | $17.3M | 115,000 | -0.02pp | 4q | -20.7%-$4.5M | |
| REGENERON PHARMACEUTICALS | REGN | $17.1M | 27,390 | -2.97pp | 18q | -43.1%-$12.9M | |
| GLAUKOS CORP | GKOS | $16.6M | 119,000 | +0.45pp | 31q | +41.7%+$4.9M | |
| BIOMARIN PHARMACEUTICAL INC | BMRN | $16.6M | 290,500 | +0.13pp | 31q | +40.3%+$4.8M | |
| NURIX THERAPEUTICS INC | NRIX | $16.6M | 684,250 | +0.97pp | 9q | +118.3%+$9.0M | |
| NATERA INC | NTRA | $16.6M | 61,050 | +0.29pp | 16q | +18.3%+$2.6M | |
| MIRUM PHARMACEUTICALS INC | MIRM | $16.3M | 139,205 | +0.48pp | 10q | +50.3%+$5.5M | |
| INSMED INC | INSM | $16.2M | 151,960 | -1.69pp | 9q | -4.9%-$831.6K | |
| TENET HEALTHCARE CORP | THC | $15.9M | 85,200 | +0.25pp | 21q | +57.8%+$5.8M | |
| THERMO FISHER SCIENTIFIC INC | TMO | $15.8M | 31,580 | -1.01pp | 26q | -23.6%-$4.9M | |
| CENTENE CORP DEL | CNC | $15.7M | 244,000 | - | new | NEW | |
| AXSOME THERAPEUTICS INC | AXSM | $15.4M | 63,050 | +0.13pp | 14q | -1.2%-$183.6K | |
| DANAHER CORP DEL | DHR | $15.3M | 80,252 | +1.02pp | 19q | +344.6%+$11.8M | |
| VERTEX PHARMACEUTICALS INC | VRTX | $15.2M | 30,685 | -0.96pp | 31q | -29.4%-$6.4M | |
| ANTERIS TECHNOLOGIES GLOBAL | AVR | $15.2M | 1,538,625 | +0.45pp | 6q | +7.0%+$985.0K | |
| NEUROCRINE BIOSCIENCES INC | NBIX | $14.5M | 85,841 | -0.27pp | 31q | -14.9%-$2.5M | |
| PENNANT GROUP INC | PNTG | $13.7M | 371,471 | +0.26pp | 3q | +34.9%+$3.5M | |
| INTUITIVE SURGICAL INC | ISRG | $13.7M | 34,500 | -0.80pp | 27q | -6.4%-$933.0K | |
| ELEVANCE HEALTH INC FORMERLY | ELV | $13.5M | 34,900 | +0.11pp | 31q | +8.0%+$1.0M | |
| LIVANOVA PLC | LIVN | $13.5M | 164,000 | +0.06pp | 5q | +5.8%+$740.1K | |
| CENCORA INC | COR | $13.2M | 46,778 | -0.78pp | 22q | -10.7%-$1.6M | |
| CHARLES RIV LABS INTL INC | CRL | $13.0M | 57,200 | +0.67pp | 3q | +120.0%+$7.1M | |
| IDEAYA BIOSCIENCES INC | IDYA | $12.8M | 343,800 | +0.16pp | 3q | +34.6%+$3.3M | |
| MCKESSON CORP | MCK | $12.5M | 16,550 | -0.62pp | 22q | -1.8%-$226.7K | |
| SYNDAX PHARMACEUTICALS INC | SNDX | $12.2M | 560,250 | +0.06pp | 10q | +47.7%+$4.0M | |
| BRIGHTSPRING HEALTH SVCS INC | BTSG | $11.6M | 165,896 | +0.83pp | 4q | +231.8%+$8.1M | |
| MEDTRONIC PLC | MDT | $11.3M | 145,000 | +0.11pp | 31q | +61.1%+$4.3M | |
| MINERALYS THERAPEUTICS INC | MLYS | $11.2M | 416,371 | +0.18pp | 4q | +58.3%+$4.1M | |
| OSCAR HEALTH INC | OSCR | $11.2M | 392,000 | +0.12pp | 3q | -40.6%-$7.6M | |
| ROYALTY PHARMA PLC | RPRX | $11.0M | 197,000 | -0.34pp | 17q | -15.5%-$2.0M | |
| DEXCOM INC | DXCM | $10.8M | 160,000 | - | new | NEW | |
| ALIGN TECHNOLOGY INC | ALGN | $10.6M | 63,000 | +0.84pp | 11q | +740.0%+$9.4M | |
| SPYRE THERAPEUTICS INC | SYRE | $10.6M | 119,300 | - | new | NEW | |
| RELAY THERAPEUTICS INC | RLAY | $10.6M | 566,000 | +0.56pp | 15q | +57.2%+$3.9M | |
| ARROWHEAD PHARMACEUTICALS IN | ARWR | $10.4M | 128,000 | -0.13pp | 3q | -11.4%-$1.3M | |
| AGILENT TECHNOLOGIES INC | A | $10.0M | 75,000 | +0.59pp | 3q | +200.0%+$6.6M | |
| NEKTAR THERAPEUTICS | NKTR | $9.9M | 141,250 | +0.41pp | 2q | +139.4%+$5.7M | |
| ALKERMES PLC | ALKS | $9.7M | 185,250 | +0.33pp | 31q | +39.0%+$2.7M | |
| ABBOTT LABORATORIES | ABT | $8.7M | 96,000 | -0.60pp | 2q | -14.3%-$1.5M | |
| DIANTHUS THERAPEUTICS INC | DNTH | $8.4M | 86,127 | -0.05pp | 8q | +5.5%+$438.7K | |
| PROCEPT BIOROBOTICS CORP | PRCT | $7.8M | 345,000 | -0.73pp | 13q | -27.4%-$2.9M | |
| STRUCTURE THERAPEUTICS INC | GPCR | $7.8M | 145,100 | -0.03pp | 6q | +13.3%+$912.4K | |
| ORUKA THERAPEUTICS INC | ORKA | $7.6M | 80,000 | - | new | NEW | |
| ENCOMPASS HEALTH CORP | EHC | $7.5M | 74,263 | +0.04pp | 10q | +32.0%+$1.8M | |
| MOONLAKE IMMUNOTHERAPEUTICS | MLTX | $7.5M | 384,800 | +0.16pp | 6q | +60.7%+$2.8M | |
| IOVANCE BIOTHERAPEUTICS INC | IOVA | $7.1M | 1,705,327 | -0.22pp | 31q | -17.0%-$1.5M | |
| BRIDGEBIO PHARMA INC | BBIO | $6.8M | 91,100 | -0.19pp | 3q | +0.6%+$37.2K | |
| KURA ONCOLOGY INC | KURA | $6.5M | 591,500 | +0.34pp | 10q | +117.9%+$3.5M | |
| INSULET CORP | PODD | $6.4M | 42,000 | +0.24pp | 11q | +200.0%+$4.3M | |
| ERASCA INC | ERAS | $6.4M | 349,000 | - | new | NEW | |
| KRYSTAL BIOTECH INC | KRYS | $6.1M | 16,325 | +0.04pp | 10q | -2.1%-$130.1K | |
| STEVANATO GROUP S P A | STVN | $5.5M | 305,972 | +0.06pp | 4q | +11.4%+$565.5K | |
| ASTRANA HEALTH INC | ASTH | $5.5M | 118,888 | - | new | NEW | |
| CARDINAL HEALTH INC | CAH | $5.3M | 22,500 | -0.20pp | 2q | -16.7%-$1.1M | |
| ALNYLAM PHARMACEUTICALS INC | ALNY | $5.2M | 17,200 | -0.92pp | 31q | -50.1%-$5.2M | |
| MOLINA HEALTHCARE INC | MOH | $5.0M | 21,857 | - | new | NEW | |
| VIKING THERAPEUTICS INC | VKTX | $5.0M | 128,000 | -0.17pp | 14q | -20.0%-$1.2M | |
| THE CIGNA GROUP | CI | $4.8M | 17,400 | +0.19pp | 31q | +117.5%+$2.6M | |
| IONIS PHARMACEUTICALS INC | IONS | $4.7M | 59,900 | -0.41pp | 9q | -35.5%-$2.6M | |
| AMN HEALTHCARE SVCS INC | AMN | $4.7M | 144,466 | - | new | NEW | |
| DENALI THERAPEUTICS INC | DNLI | $4.6M | 179,000 | -0.04pp | 6q | -10.1%-$514.4K | |
| MEDPACE HLDGS INC | MEDP | $4.5M | 8,500 | - | new | NEW | |
| MADRIGAL PHARMACEUTICALS INC | MDGL | $4.3M | 8,050 | -1.15pp | 4q | -66.5%-$8.6M | |
| AMGEN INC | AMGN | $4.3M | 11,900 | -0.25pp | 3q | -21.7%-$1.2M | |
| SIONNA THERAPEUTICS INC | SION | $4.3M | 97,100 | -0.03pp | 2q | +11.0%+$422.3K | |
| ASCENDIS PHARMA A/S | ASND | $4.0M | 15,000 | - | new | NEW | |
| COOPER COS INC | COO | $3.9M | 54,000 | -0.08pp | 10q | +8.0%+$286.8K | |
| WAYSTAR HLDG CORP | WAY | $3.7M | 178,566 | -0.67pp | 2q | -47.9%-$3.4M | |
| MBX BIOSCIENCES INC | MBX | $3.4M | 62,000 | - | new | NEW | |
| VERICEL CORP | VCEL | $3.1M | 70,000 | +0.02pp | 5q | HELD | |
| VEEVA SYS INC | VEEV | $3.1M | 17,300 | -1.56pp | 2q | -79.7%-$12.1M | |
| BICARA THERAPEUTICS INC | BCAX | $2.6M | 88,150 | - | new | NEW | |
| STERIS PLC | STE | $2.4M | 11,500 | -0.09pp | 3q | HELD | |
| OCULAR THERAPEUTIX INC | OCUL | $2.2M | 225,000 | -0.11pp | 4q | -26.2%-$785.6K | |
| STOKE THERAPEUTICS INC | STOK | $2.1M | 64,500 | -0.13pp | 4q | -22.3%-$605.3K | |
| XENON PHARMACEUTICALS INC | XENE | $2.0M | 33,250 | -0.01pp | 9q | +18.8%+$316.9K | |
| DOXIMITY INC | DOCS | $1.6M | 76,107 | -0.38pp | 5q | -58.6%-$2.2M | |
| PRIVIA HEALTH GROUP INC | PRVA | $1.3M | 50,000 | - | new | NEW | |
| NOVOCURE LTD | NVCR | $1.1M | 70,000 | +0.01pp | 2q | HELD | |
| MINIMED GROUP INC | MMED | $822.2K | 55,000 | - | new | NEW | |
| ALPHATEC HLDGS INC | ATEC | $735.2K | 85,000 | -0.02pp | 4q | +21.4%+$129.8K | |
| AGILON HEALTH INC | AGL | $535.9K | 5,000 | - | new | NEW | |
| 10X GENOMICS INC | TXG | $325.9K | 8,500 | - | new | NEW | |
| TANDEM DIABETES CARE INC | TNDM | $301.8K | 20,000 | - | new | NEW | |
| TG THERAPEUTICS INC | TGTX | $274.7K | 5,000 | - | new | NEW |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $568.8M | 53.7% |
| Medical Devices | $183.9M | 17.4% |
| Healthcare Services | $113.3M | 10.7% |
| Insurance | $112.8M | 10.6% |
| Instruments & Controls | $31.1M | 2.9% |
| Wholesale & Distribution | $31.1M | 2.9% |
| Other sectors | $18.5M | 1.7% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $1.1B | 99 | 21 | 41 | 34 | 8 | 25.1% | 44 |
| Q1 2026 | $810.5M | 86 | 11 | 29 | 42 | 19 | 32.0% | 44 |
| Q4 2025 | $1.1B | 94 | 13 | 43 | 32 | 11 | 29.4% | 44 |
| Q3 2025 | $903.7M | 92 | 13 | 46 | 23 | 11 | 30.1% | 44 |
| Q2 2025 | $791.0M | 90 | 11 | 28 | 37 | 15 | 32.9% | 44 |
| Q1 2025 | $870.0M | 94 | 12 | 20 | 55 | 10 | 34.3% | 44 |
| Q4 2024 | $972.9M | 92 | 2 | 29 | 54 | 5 | 31.9% | 44 |
| Q3 2024 | $1.2B | 95 | 8 | 38 | 37 | 6 | 30.7% | 44 |
| Q2 2024 | $1.0B | 93 | 14 | 36 | 30 | 5 | 35.4% | 44 |
| Q1 2024 | $1.1B | 84 | 11 | 30 | 41 | 12 | 34.9% | 44 |
| Q4 2023 | $1.0B | 85 | 15 | 28 | 32 | 15 | 34.8% | 44 |
| Q3 2023 | $927.5M | 85 | 4 | 25 | 17 | 2 | 34.3% | 44 |
| Q2 2023 | $948.7M | 83 | 10 | 21 | 41 | 15 | 31.3% | 42 |
| Q1 2023 | $910.9M | 88 | 4 | 33 | 45 | 9 | 30.9% | 42 |
| Q4 2022 | $958.5M | 93 | 7 | 31 | 18 | 4 | 27.3% | 44 |
| Q3 2022 | $955.0M | 90 | 8 | 32 | 32 | 4 | 28.2% | 45 |
| Q2 2022 | $880.1M | 86 | 8 | 26 | 39 | 11 | 31.7% | 43 |
| Q1 2022 | $1.0B | 89 | 5 | 11 | 65 | 8 | 28.6% | 43 |
| Q4 2021 | $1.5B | 92 | 7 | 28 | 25 | 7 | 31.4% | 42 |
| Q3 2021 | $1.4B | 92 | 3 | 34 | 20 | 5 | 29.3% | 43 |
| Q2 2021 | $1.5B | 94 | 9 | 29 | 33 | 7 | 26.2% | 44 |
| Q1 2021 | $1.4B | 92 | 13 | 36 | 31 | 4 | 28.6% | 44 |
| Q4 2020 | $1.2B | 83 | 15 | 27 | 28 | 14 | 30.1% | 19 |
| Q3 2020 | $1.1B | 82 | 1 | 36 | 12 | 13 | 31.0% | 13 |
| Q2 2020 | $925.6M | 94 | 14 | 25 | 45 | 5 | 29.7% | 16 |
| Q1 2020 | $713.8M | 85 | 3 | 39 | 32 | 12 | 30.9% | 16 |
| Q4 2019 | $912.5M | 94 | 16 | 30 | 36 | 15 | 28.6% | 17 |
| Q3 2019 | $797.7M | 93 | 9 | 22 | 41 | 4 | 29.7% | 16 |
| Q2 2019 | $907.9M | 88 | 7 | 26 | 31 | 12 | 29.3% | 22 |
| Q1 2019 | $854.9M | 93 | 12 | 18 | 37 | 8 | 29.5% | 11 |
| Q4 2018 | $874.8M | 89 | 0 | 0 | 0 | 0 | 28.8% | 36 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.